Medx Health Blockbuster Potential !

WKN: A0YJHF

  MedX Health Corp. (MDX)
 
Hallo ARIVA User,

wer nach guten Performancechanchen sucht sollte sich BITTE die Aktie der MedX Health Corp. genauer anschauen. Ich schreibe heute nicht viel - denn jeder soll sich selbst ein Bild von der signifikanten Chance machen.Fakt ist eines - Diese Aktie dürfte sich aus dem Stand sogar verfünffachen - in den USA gibt es erste Rumors zu bevorstehenden signifikanten Unternehmensnews. Bei einem Börsenwert von sage und schreibe NUR 1,3 Millionen €  und einem geschätzen Marktpotential von mehreren 100 Mio US $ ist es nur noch eine Frage der Zeit bis die Aktie wie Phönix aus der Asche nach oben schiesst.

Am Freitag schloss die Aktie in Canada mit 30 % im Plus. Dies ist der Beginn einer signifikanten Neubewertung der Aktie. Ein fairer Wert dürfte zwischen 1,30 - 1,80 $ gesehen werden. Bei einem derzeitigen Kurs von nur 0,065 $ eine überdurchschnittliche Renditeerwartung.

__________________________________________________

www.munknee.com/2012/05/...investment-in-your-health-and-your-wealth/

 
This Skin Cancer Detection Device Could Be a Great Investment in Your Health – and Your Wealth

 

  www.simsys-molemate.com/

www.medxhealth.com/index.html

 

__________________________________________________

 
Major products and inventions consumers should watch for in 2013

www.consumeraffairs.com/news/...-should-watch-for-in-2013-011413.html

 
The Molemate

Almost every year, scientists and researchers announce a new finding or medical breakthrough that has a huge impact on all of us, and so far there’s been a lot of talk about a skin cancer-detecting device called the MoleMate Skin Imaging System, which allows dermatologists to test for melanoma by just running the device along the skin, instead of doing an invasive procedure like a biopsy.

The inventor of the handheld device, Symon Cotton, says physicians will be able to read the machine's light waves to detect melanoma without having to remove a portion of the skin.The MoleMate “operates by using wave lengths of light that interact with different cells in different ways,” said Cotton in an informational video about the device. “Because we know how they interact with these cells we can identify what’s in the skin without having to do a biopsy, i.e. cut a piece of the skin out.”The company also says the MoleMate is extremely easy to use, as one pretty much just has to hold the oblong device to a patient’s skin.What’s also terrific about the device is that physicians will be able to learn how to use it in just a couple of hours. It’s also said the device will be able to detect melanoma at earlier stages and provide more accurate readings.

Although there hasn’t been an exact release date of the Molemate, it has already been approved by the FDA and is rumored to hit U.S. doctor offices by this year. Hopefully by 2014 it will be a device commonly used by dermatologists.

__________________________________________________
 
 

 

 

Unilever usw. uws. Produkt Partner von Medx Health. Corp.

 

...... zu MoleMate ! Gerüchte über eine weitere Meilenstein "News" und zufällig startete die Aktie am Freitag in Canada kräftig durch.  Da braucht man doch nur noch 1 + 1 zusammenzählen um zu begreifen das die Aktie eine kräftige Rallye begonnen hat die locker bis in den Bereich 1 $ / Aktie laufen kann.

__________________________________________________

"Although there hasn’t been an exact release date of the Molemate, it  has already been approved by the FDA and is rumored to hit U.S. doctor  offices by this year. Hopefully by 2014 it will be a device commonly  used by dermatologists."

 

aber verdächtig große Käufe! Das riecht nach News,entweder Übernahme oder ähnliches.
Plus 20 % an der TSX unter sehr guten Umsätzen.

Denke da kommt die Übernahme...................  

TH  

Verisante Technology, Inc. Announces First Sales of Aura, a Revolutionary Medical Device for the Detection of Skin Cancer

2013-01-30 10:36 ET - News Release

VANCOUVER, BRITISH COLUMBIA -- (MARKET WIRE) -- 01/30/13

Verisante Technology, Inc. (TSX VENTURE:VRS)(OTCQX:VRSEF)(FRANKFURT:V3T) (the "Company" or "Verisante"), a leader in cancer detection technology, announced today that the Company has received purchase orders for Verisante Aura(TM) from the Company's exclusive distributors in Canada and Europe.

"This is a significant achievement for our Company as we take this ground-breaking technology to full commercialization," said Thomas Braun, President & CEO of Verisante. "The Company has been working very closely with our distribution partners on a strategic product launch. With manufacturing of Aura(TM) now underway and the full support of our distributors, 2013 is already shaping up to be a very successful year for our Company."

Verisante anticipates it will begin shipping Aura(TM) devices in February and will update the new Aura(TM) website with a list of clinics where patients can go to request an AuraScan(TM) when installations have been completed. Future reports of revenues and sales can be expected on a quarterly basis along with the reporting of our financial statements.

"Aura(TM) has the potential to revolutionize the way skin cancer is diagnosed," said Dan Webb, CEO of Clarion, exclusive Canadian distributor. "Clarion is committed to bringing this life-saving technology to medical professionals across Canada."

Dr. Barry Lycka, MD, a board-certified dermatologist and founder of the Canadian Skin Cancer Foundation, sees Aura(TM) becoming an integral part of the practice of any dermatologist who is diagnosing and treating skin cancer. "With the incidence of skin cancers on the rise and very few tools available to dermatologists to assist in the biopsy decision, I very much welcome a device such as Aura(TM)," said Dr. Lycka, who practises in Edmonton (Alberta). "Clinical study results have shown that the device is fast, accurate and effective in improving patient outcomes."

In Europe, Michael Landsberg, President of Laserwelt, is excited to have the first Aura(TM) device available to German-speaking countries. "With the exclusive distribution rights for Aura(TM) in Germany, Austria and Liechtenstein, Laserwelt is ready to begin our sales and marketing efforts to the region's over 10,000 dermatologists and skin care specialists," said Landsberg. "The German market is highly scientific and sophisticated, and it can be a difficult market for new technologies to penetrate. However, with our depth of industry contacts and network of key opinion leaders in world-renowned University clinics, Laserwelt is in a unique position to bring these decisions makers together and introduce them to Aura's(TM) strong clinical study results, which we are confident will amount to significant sales."

And Dr. Henk-Peter Oonk, CEO of bo pharma BV is confident that Aura(TM) will be very well received in the Benelux region, where traditionally new technologies are adopted quickly. "Recent expansion of our exclusive distribution agreement for Aura(TM) to include the Nordic countries in addition to the Benelux region underlines our confidence in this product and this technology as we prepare for product launch."

Verisante Aura(TM) is indicated for use for the evaluation of skin lesions that may be clinically suspicious for melanoma, squamous cell carcinoma and/or basal cell carcinoma when a medical professional chooses to obtain additional information to rule out one of the above conditions before making a final decision to biopsy. Aura(TM) is a non-invasive optical system that uses Raman spectroscopy to biochemically analyze the skin, providing immediate and accurate results. The device will help to automate the current process of diagnosis, allowing rapid scanning of the 20 to 40 skin lesions on at-risk individuals, improving patient outcomes and comfort.

For information about purchasing an Aura(TM) in Canada, contact Clarion Medical Technologies at: info@clarionmedical.com

For information about purchasing Aura(TM) in Germany, contact Laserwelt at: info@laserwelt.com

For information about purchasing Aura(TM) in Belgium, the Netherlands, Luxembourg, Sweden, Norway, Denmark, Finland or Iceland, contact bo pharma at: info@bo-pharma.com

About Verisante Technology, Inc.

Verisante is a medical device company committed to commercializing innovative systems for the early detection of cancer. The Verisante Aura(TM) for skin cancer detection and the Verisante Core(TM) series for lung, colon and cervical cancer detection utilize a proprietary cancer detection platform while the operating software and probe technology are unique to each device. The cancer detection platform was developed by the BC Cancer Agency and tested and refined at the Skin Care Centre at Vancouver General Hospital. This exclusive platform technology allows Verisante to develop and offer a range of compact, non-invasive cancer detection devices that offer physicians immediate results for many of the most common cancers. Aura(TM) has been approved for sale in Canada, Europe and Australia. The Core(TM) has not yet been approved for sale.

Verisante Aura(TM) was awarded Popular Science Magazine's "Best of What's New Award" for 2011, and Verisante Core(TM) was named one of the top 10 cancer breakthroughs of 2011 by the Canadian Cancer Society.

Website: www.verisante.com

Youtube: www.youtube.com/verisante

Twitter: www.twitter.com/verisante

Facebook: www.facebook.com/verisante

Forward Looking Statements

This release contains forward-looking statements, including, but not limited to, statements regarding the future commercialization of medical devices, the market demand for these products and the proprietary protections the Company will obtain with regard to the technology, all of which statements are subject to market risks, and the possibility that the Company will not be able to obtain patent protection or obtain sufficient customer demand. These statements are made based upon current expectations and actual results may differ from those projected due to a number of risks and uncertainties.

The TSX Venture Exchange has neither approved nor disapproved of the contents of this press release. Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release.

Contacts:
Verisante Technology, Inc.
Thomas Braun
President & CEO
(604) 605-0507
info@verisante.com
www.verisante.com  

Verisante 39 Millionen CAD $ Börsenwert

MedX Healt Corp. lächerliche 1,8 Millionen CAD $ - MedX Health bei Übernahme mind. 1 $ / Aktie

 

http://investmentunderground.com/5904/featured/verisante-technology-advancing-skin-cancer-detection-to-save-lives/

 

 

New Skin Cancer Detection Devices

In a very  short amount of time, companies including Verisante (VRSEF) have  developed devices that use raman spectroscopy to determine the presence  of skin cancer. Verisante recently renewed  its partnership with the BC Cancer Agency to continue performing  research and testing on its skin cancer detection device, the Verisante  Aura. This means the company will continue to invest revenue and time  into perfecting the device.

In addition to detecting skin cancer, the company has another device, the Verisante Core, which aids in the detection of lung, cervical, and colon cancer.

Other  companies trying to prevent the spread of skin cancer through the use  of early detection devices include MELA Sciences (MELA) and MedX Health  Corporation (MDX). MELA Sciences, which received both EU and FDA approval for its detection device MelaFind, was designed to detect melanoma in patients.

MedX Health Corporation, a company based in Canada, received approval to sell its skin cancer detection device, MoleMate in Canada at the beginning of this year.

As  more and more companies develop skin cancer and other cancer detection  devices, technologies like raman spectroscopy will become even more  advanced.

Skin Cancer Detection Device Market

A  niche market within the skin cancer prevention and treatment market,  the skin cancer detection market has the potential to bring in steady  profits for investors. Marketed mostly to dermatologists, these devices  may also be used by general practitioners and clinicians in remote areas  with few skin cancer specialists. Portable and easy to use, these  devices have the ability to help save countless lives through early  detection. Since most forms of skin cancer are preventable and  treatable, the number of fatalities due to skin cancer should decline  steadily once these devices become accepted and used in more and more  areas.

Investors looking for a safe, long-term investment should  consider this market. According to the American Academy of Dermatology,  an estimated  1 in 50 people in the U.S. will be diagnosed with melanoma each year.  This means the need for these types of devices will continue to  increase.

Skin Cancer Testing

In addition to increased occurrences of skin cancer, testing for cancer has grown over the years. By 2017, cancer testing revenues  will reach about $11.46 billion. With a need for accuracy and ease of  testing, more and more physicians and dermatologists will require  top-notch skin cancer detection devices. For investors, this could prove  very profitable for a very long period of time.

The market  potential for skin cancer testing could move beyond the medical office.  Home devices may eventually help people diagnose the presence of skin  cancer without physician assistance. This could open up a whole new  market for investors as well as manufacturers and product developers.  And while home testing devices may be a few years away, investors should  consider how these devices will evolve in the future.

Since skin  cancer, if found early, may be treated under a physician’s care, devices  like these should only become more popular over time. Treating skin  cancer early not only saves lives, but also cuts medical costs for  patients and insurance companies. This alone should help these detection  devices find a solid place in the prevention and treatment of skin  cancer.

 

400,000 Aktien Umsatz Kurs  0,06 $ TH die letzte News brachte der Aktie 500 % intraday auf über 0,31 $ !

Aktuell 0,06 $ und es riecht nach einer  guten News  

Übernahme ? Von der Zeit her könnte das passen dazu die hohen Umsätze in Canada ...........

 

"and identify potential acquisition, divestiture or merger opportunities"

 

MedX Health hires Byron as strategic adviser  2012-12-05 15:35 ET - News Release    Mr. Louie Canitano reports  

 

MEDX HEALTH CORP. ENTERS INTO ADVISORY AGREEMENT WITH BYRON CAPITAL MARKETS  MedX Health Corp. (MDX) has entered into an advisory agreement with Byron Capital Markets Ltd.  Byron will, over a two-month period commencing on the date of signature of the agreement, facilitate MDX's access to capital markets, and identify potential acquisition, divestiture or merger opportunities. In addition, Byron will provide strategic advice to MDX with the intent to maximize shareholder value, assist with introduction to potential strategic investors and assist MDX in structuring future transactions.  MDX will pay Byron a total fee of $200,000, payable as to $100,000 in cash and $100,000 in common shares of the corporation. The issue price of the shares will be calculated pursuant to the policies of the TSX Venture Exchange, and will be subject to all relevant regulatory and other consents and approvals.  We seek Safe Harbor.

 

du irgendwo eine gute seite wo ich die kurse bzw geld/brief bzw l2 sehe?
Möchte ja nicht auf geratwohl kaufen.

Thx  

http://tmx.quotemedia.com/research.php?qm_symbol=MDX  

bin gespannt wie das hier weiter geht. :)  

man schaue sich die dicken Käufer in canada an. seit tagen wird sich still und heimlich eingekauft. das riecht nach News. die letzte News brachte intraday über 400 %
schöne einstiegschance bei der niedrigen mcap  

0,07 Tageshoch und dicke Umsätze
bald 1 $ ?  

jup ist mir heute auch aufgefallen...gestern ging ja gar nichts und da wollte ich heute mal nachkaufen, aber war dann schon zu spät.
Soll mir aber auch recht sein, solange es up geht :)  

ist auch gut...hat da wirklich einer 15k zu 0.059 gekauft :)

+0,035 €
+145,83%

so gefällts mir  

Düfte in kürze fallen da ist ein dicker fisch an der angel. je nach deal 2 - 5 $ Aktie  

also auch für  

mit Kaufsignal.Über 0,10 $ gehts richtig ab oder bei Übernahme News außerhalb Handel Eröffnung zw. 1 $ - 3 $ möglich !?

 

ca.hotstocked.com/article/30301/canadian-market-now-open-for-medx­-health-corp.html

 

MedX Health Corp. ( CVE:MDX ) (PINK:MDXHF) stock price skyrocketed after the company got

... (automatisch gekürzt) ...

http://ca.hotstocked.com/article/30301/...n-for-medx-health-corp.html

 

schon vor einem Jahr stattfinden:

www.medxhealth.com/documents/...tructuing_and_AGM_081310.pdf#zoom=100

Bald gehts los:

 

 

 

Oh, eine neue Abzockbude.  

Keine Abzockbude ohne Propaganda.

 

 

 

lemminge...heute ist wiedermal schlaftablette angesagt ;)  

der dumm push Adel

fährt auf...


na dann, ist klar wohin die Reise geht .-)

n.m.p.M.